PL352402A1 - Pharmaceutical composition containing sibutramine and orlistat - Google Patents
Pharmaceutical composition containing sibutramine and orlistatInfo
- Publication number
- PL352402A1 PL352402A1 PL00352402A PL35240200A PL352402A1 PL 352402 A1 PL352402 A1 PL 352402A1 PL 00352402 A PL00352402 A PL 00352402A PL 35240200 A PL35240200 A PL 35240200A PL 352402 A1 PL352402 A1 PL 352402A1
- Authority
- PL
- Poland
- Prior art keywords
- orlistat
- pharmaceutical composition
- composition containing
- containing sibutramine
- sibutramine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9914744.9A GB9914744D0 (en) | 1999-06-24 | 1999-06-24 | Therapeutic agents |
PCT/EP2000/005542 WO2001000205A1 (en) | 1999-06-24 | 2000-06-16 | Pharmaceutical composition containing sibutramine and orlistat |
Publications (1)
Publication Number | Publication Date |
---|---|
PL352402A1 true PL352402A1 (en) | 2003-08-25 |
Family
ID=10855955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL00352402A PL352402A1 (en) | 1999-06-24 | 2000-06-16 | Pharmaceutical composition containing sibutramine and orlistat |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1187606A1 (en) |
JP (1) | JP2003503349A (en) |
KR (1) | KR20020015357A (en) |
CN (1) | CN1358092A (en) |
AU (1) | AU5533200A (en) |
BG (1) | BG106180A (en) |
BR (1) | BR0011880A (en) |
CA (1) | CA2375972A1 (en) |
CZ (1) | CZ20014613A3 (en) |
GB (1) | GB9914744D0 (en) |
HK (1) | HK1049278A1 (en) |
HU (1) | HUP0201878A3 (en) |
IL (1) | IL147079A0 (en) |
MX (1) | MXPA01012936A (en) |
NO (1) | NO20016224L (en) |
PL (1) | PL352402A1 (en) |
RU (1) | RU2229289C2 (en) |
SK (1) | SK18242001A3 (en) |
TR (1) | TR200103699T2 (en) |
WO (1) | WO2001000205A1 (en) |
ZA (1) | ZA200109989B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6696495B2 (en) * | 1998-12-02 | 2004-02-24 | Snowden Pharmaceuticals, Llc | Treatment of disorders secondary to organic impairments |
US20040214804A1 (en) * | 2003-04-25 | 2004-10-28 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and an anti-obesity agent |
JP2008517976A (en) | 2004-10-25 | 2008-05-29 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | A pharmaceutical composition for the treatment of diabetes mellitus type 1, obesity and related symptoms, comprising a CB1 cannabinoid receptor antagonist and a potassium channel opener |
US8604244B2 (en) | 2010-07-02 | 2013-12-10 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives |
JP2010503709A (en) | 2006-09-15 | 2010-02-04 | レビバ ファーマシューティカルズ,インコーポレーテッド | Synthesis, methods of use and compositions of cycloalkylmethylamines |
AU2007322477A1 (en) * | 2006-11-22 | 2008-05-29 | Sk Chemicals Co., Ltd. | Inclusion complex of sibutramine and beta-cyclodextrin |
CN101890017A (en) * | 2009-05-22 | 2010-11-24 | 北京奥萨医药研究中心有限公司 | Medicament composition containing sibutramine and stanin fat-reducing medicament and application thereof |
MX336980B (en) | 2010-12-21 | 2016-02-09 | Senosiain S A De C V Lab | Combination and composition for treating obesity. |
KR20140110014A (en) | 2011-12-30 | 2014-09-16 | 레비바 파마슈티칼스, 아이엔씨. | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9727131D0 (en) * | 1997-12-24 | 1998-02-25 | Knoll Ag | Therapeutic agents |
-
1999
- 1999-06-24 GB GBGB9914744.9A patent/GB9914744D0/en not_active Ceased
-
2000
- 2000-06-16 CN CN00809372A patent/CN1358092A/en active Pending
- 2000-06-16 RU RU2002102076/14A patent/RU2229289C2/en not_active IP Right Cessation
- 2000-06-16 SK SK1824-2001A patent/SK18242001A3/en unknown
- 2000-06-16 TR TR2001/03699T patent/TR200103699T2/en unknown
- 2000-06-16 HU HU0201878A patent/HUP0201878A3/en unknown
- 2000-06-16 MX MXPA01012936A patent/MXPA01012936A/en unknown
- 2000-06-16 WO PCT/EP2000/005542 patent/WO2001000205A1/en not_active Application Discontinuation
- 2000-06-16 EP EP00940379A patent/EP1187606A1/en not_active Withdrawn
- 2000-06-16 BR BR0011880-0A patent/BR0011880A/en not_active IP Right Cessation
- 2000-06-16 CZ CZ20014613A patent/CZ20014613A3/en unknown
- 2000-06-16 CA CA002375972A patent/CA2375972A1/en not_active Abandoned
- 2000-06-16 KR KR1020017016575A patent/KR20020015357A/en not_active Application Discontinuation
- 2000-06-16 IL IL14707900A patent/IL147079A0/en unknown
- 2000-06-16 JP JP2001505914A patent/JP2003503349A/en active Pending
- 2000-06-16 AU AU55332/00A patent/AU5533200A/en not_active Abandoned
- 2000-06-16 PL PL00352402A patent/PL352402A1/en not_active Application Discontinuation
-
2001
- 2001-12-04 BG BG106180A patent/BG106180A/en unknown
- 2001-12-05 ZA ZA200109989A patent/ZA200109989B/en unknown
- 2001-12-19 NO NO20016224A patent/NO20016224L/en not_active Application Discontinuation
-
2003
- 2003-01-09 HK HK03100246.9A patent/HK1049278A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1358092A (en) | 2002-07-10 |
AU5533200A (en) | 2001-01-31 |
SK18242001A3 (en) | 2003-02-04 |
CZ20014613A3 (en) | 2003-04-16 |
HUP0201878A3 (en) | 2005-04-28 |
WO2001000205A1 (en) | 2001-01-04 |
RU2229289C2 (en) | 2004-05-27 |
HK1049278A1 (en) | 2003-05-09 |
NO20016224L (en) | 2002-02-12 |
KR20020015357A (en) | 2002-02-27 |
EP1187606A1 (en) | 2002-03-20 |
ZA200109989B (en) | 2003-02-26 |
BG106180A (en) | 2002-08-30 |
IL147079A0 (en) | 2002-08-14 |
BR0011880A (en) | 2002-03-19 |
JP2003503349A (en) | 2003-01-28 |
GB9914744D0 (en) | 1999-08-25 |
NO20016224D0 (en) | 2001-12-19 |
HUP0201878A2 (en) | 2003-08-28 |
CA2375972A1 (en) | 2001-01-04 |
TR200103699T2 (en) | 2002-04-22 |
MXPA01012936A (en) | 2004-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200110022B (en) | Thiazoloderivatives and pharmaceutical compositions containing them. | |
IL144977A0 (en) | Pyrrolotriazine derivatives and pharmaceutical compositions containing the same | |
IL150224A0 (en) | Lipopeptides and pharmaceutical compositions containing the same | |
HRP20060251B1 (en) | Substituted oxasolidinones and their use | |
IL150223A0 (en) | Lipopeptides and pharmaceutical compositions containing the same | |
HUP0200548A2 (en) | Pharmaceutical compositions and their use | |
HUP0103884A3 (en) | Arylsulfonanilide urea-derivatives, pharmaceutical compositions containing them and their use | |
HUP0204081A3 (en) | 4-pyrimidinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use | |
IL135646A0 (en) | α-ARYL-N-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
HUP0001309A3 (en) | 1-phenyl-4-benzylpiperazines and pharmaceutical compositions containing them | |
HUP0203194A3 (en) | Phenylpiperazines, pharmaceutical compositions containing them and their use | |
HUP0203735A3 (en) | 4-pyridinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use | |
IL133097A0 (en) | Aroyl-piperazine derivatives pharmaceutical compositions containing the same and the use thereof | |
IL147214A0 (en) | 1-methylcarbapenem derivatives and pharmaceutical compositions containing the same | |
HUP9802132A3 (en) | Biphenyl-sulfonyl-cyanamides, their use and pharmaceutical compositions containing them | |
HUP0200055A3 (en) | 16-hydroxyestrienes and pharmaceutical compositions containing the same | |
HUP0101733A3 (en) | Pharmaceutical compositions containing sulfonyl-dipeptides and their use | |
HUP0201878A3 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
EG22491A (en) | Rest-breaking composition and use thereof | |
HUP0103006A3 (en) | Substituted betha-diketones, pharmaceutical compositions containing them and their use | |
SI1039900T1 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
GB9911606D0 (en) | Composition and use | |
ZA9811105B (en) | Cosmetic and pharmaceutical composition | |
GB9929581D0 (en) | Comjpositions and their use | |
HUP9903500A3 (en) | Thiophene-, furane- and pyrrolesulfonamides, their use and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |